JNJ — Johnson & Johnson Share Price
Last trade - 00:00- $572.91bn
- $554.34bn
- $94.19bn
- 71
- 48
- 98
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.42 | ||
| PEG Ratio (f) | 0.95 | ||
| EPS Growth (f) | 27.54% | ||
| Dividend Yield (f) | 2.24% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.08 | ||
| EV to EBITDA | 17.06 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | 76.41% | ||
| Operating Margin | 34.59% | ||
Financial Summary
| Year End 28th Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 78,740 | 79,990 | 85,159 | 88,821 | 94,193 | 100,532.79 | 106,160.74 | 2.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +2.15 | +2.14 | +14.33 | -0.04 | +6.05 | +30.59 | +8.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Directors
- Alex Gorsky CHM (60)
- Joaquin Duato CEO (59)
- Joseph Wolk CFO (54)
- Peter Fasolo CHO (58)
- Michael Ullmann EVP (62)
- Ashley Mcevoy EVP (50)
- Thibaut Mongon EVP (51)
- Michael Sneed EVP (61)
- Jennifer Taubert EVP (57)
- Kathryn Wengel EVP (55)
- Anne Mulcahy LED (68)
- Mary Beckerle IND (66)
- D. Scott Davis IND (69)
- Ian Davis IND (70)
- Jennifer Doudna IND (57)
- Marillyn Hewson IND (67)
- Hubert Joly IND (61)
- Mark Mcclellan IND (57)
- Charles Prince IND (71)
- A. Eugene Washington IND (70)
- Mark Weinberger IND (59)
- Nadja West IND (60)
- Ronald Williams IND (71)
- Last Annual
- December 28th, 2025
- Last Interim
- December 28th, 2025
- Incorporated
- November 10th, 1887
- Public Since
- September 25th, 1944
- No. of Employees
- 138,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,409,295,102
- Address
- One Johnson & Johnson Plaza, NEW BRUNSWICK, 08933
- Web
- https://www.jnj.com/
- Phone
- +1 7325242455
- Contact
- Jessica Moore
- Auditors
- PricewaterhouseCoopers LLP
Latest News for JNJ
Upcoming Events for JNJ
Dividend For JNJm.BA - 0.0867 USD
Dividend For JNJ.TO - 0.1676 CAD
Dividend For JNJB34.SA - 0.4712 BRL
Dividend For JNJ.N - 1.3000 USD
Johnson & Johnson at TD Cowen Healthcare Conference
Q1 2026 Johnson & Johnson Earnings Release
Johnson & Johnson Annual Shareholders Meeting
Q2 2026 Johnson & Johnson Earnings Release
Similar to JNJ
Abbvie
New York Stock Exchange
AstraZeneca
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
FAQ
As of Today at 02:28 UTC, shares in Johnson & Johnson are trading at $237.79. This share price information is delayed by 15 minutes.
Shares in Johnson & Johnson last closed at $237.79 and the price had moved by +53.72% over the past 365 days. In terms of relative price strength the Johnson & Johnson share price has outperformed the S&P500 Index by +37.56% over the past year.
The overall consensus recommendation for Johnson & Johnson is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Johnson & Johnson dividend yield is 2.19% based on the trailing twelve month period.
Last year, Johnson & Johnson paid a total dividend of $5.20, and it currently has a trailing dividend yield of 2.19%.Looking ahead, shares in Johnson & Johnson are due to go ex-dividend on 2026-02-24 and the next dividend pay date is 2026-03-10.
Johnson & Johnson are due to go ex-dividend on 2026-02-24 and the next dividend pay date is 2026-03-10. The historic dividend yield on Johnson & Johnson shares is currently 2.19%.
To buy shares in Johnson & Johnson you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $237.79, shares in Johnson & Johnson had a market capitalisation of $572.91bn.
Here are the trading details for Johnson & Johnson:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: JNJ
Based on an overall assessment of its quality, value and momentum Johnson & Johnson is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Johnson & Johnson is $230.53. That is 3.05% below the last closing price of $237.79.
Analysts covering Johnson & Johnson currently have a consensus Earnings Per Share (EPS) forecast of $11.54 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Johnson & Johnson. Over the past six months, its share price has outperformed the S&P500 Index by +28.61%.
As of the last closing price of $237.79, shares in Johnson & Johnson were trading +31.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Johnson & Johnson PE ratio based on its reported earnings over the past 12 months is 20.42. The shares last closed at $237.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Johnson & Johnson's management team is headed by:
- Alex Gorsky - CHM
- Joaquin Duato - CEO
- Joseph Wolk - CFO
- Peter Fasolo - CHO
- Michael Ullmann - EVP
- Ashley Mcevoy - EVP
- Thibaut Mongon - EVP
- Michael Sneed - EVP
- Jennifer Taubert - EVP
- Kathryn Wengel - EVP
- Anne Mulcahy - LED
- Mary Beckerle - IND
- D. Scott Davis - IND
- Ian Davis - IND
- Jennifer Doudna - IND
- Marillyn Hewson - IND
- Hubert Joly - IND
- Mark Mcclellan - IND
- Charles Prince - IND
- A. Eugene Washington - IND
- Mark Weinberger - IND
- Nadja West - IND
- Ronald Williams - IND